Descriptions:
| Term | description type | Language/acceptability | Language/acceptability | Case significance |
|---|---|---|---|---|
| Product containing precisely [substance][number][SI unit of mass]/[1] each [dose form] (clinical drug) | FSN | us:P | gb:P | ci |
| [substance] [SI unit of mass] [dose form] | SYN | us:P | gb:P | ci |
Concept model:
| Attribute | Value | role group number | role group cardinality |
|---|---|---|---|
| 0 | N/A | ||
| 0 | 1..1 | ||
| 0 | 1..1 | ||
| 0 | 1..1 | ||
| 1 | 1..1 | ||
| 1 | |||
| 1 | |||
| 1 | |||
| 1 | |||
| 1 |
Definition status:
900000000000073002 |Defined (core metadata concept)|
Rules for description generation:
- Remove the semantic tags, (substance) (unit of presentation) (dose form) and (qualifier value)
- For clinical drug PT SI Unit of mass uses the PT which is an abbreviation e.g. mg
- A Preferred Term (PT) for both US and GB dialect as per the substance concept terming must be added where there are US and GB spelling variations (language acceptability P/A)
Align case sensitivity with substance term
If BOSS differs from precise active ingredient BoSS <> Precise active ingredient:
FSN Product containing precisely [substance](as[substance]) [number][SI unit of mass]/[1] each [dose form] (clinical drug) e.g Product containing precisely doxazosin (as doxazosin mesilate) 8 milligram/1 each prolonged-release oral tablet (clinical drug)PT [substance] (as[substance]) [SI unit of mass PT] [dose form] e.g. US with GB language Acceptability:
Doxazosin (as doxazosin mesylate) 8 mg prolonged-release oral tablet Preferred Doxazosin (as doxazosin mesilate) 8 mg prolonged-release oral tablet Acceptable - Exceptions:use of 'actuation' -
Product containing precisely budesonide 200 microgram/actuation conventional release powder for inhalation (clinical drug)
JIRA ticket for implementation:
DRUGS-276 - Getting issue details... STATUS